v3.26.1
Segment Reporting
 3 Months Ended
Apr. 03, 2026
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our President and Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our President and Chief Executive Officer uses net income to monitor budget versus actual results for purposes of evaluating performance and to make decisions about the allocation of resources.
Our significant segment expenses that are regularly provided to our President and Chief Executive Officer and included in the measure of segment net income consist of consolidated expenses for our operational departments: drug discovery, development, and selling, general and administrative and other segment items.
The segment and consolidated net income, including significant segment expenses were as follows (in thousands):

Three Months Ended March 31,

20262025
Revenues$610,812 $555,447 
Less:
Cost of goods sold19,953 19,172 
Drug discovery19,476 18,253 
Development135,715 153,217 
Selling, general, and administrative122,870 120,775 
Other segment items(1)
61,238 57,416 
Interest income(16,127)(19,076)
Provision for income taxes57,220 46,074 
Segment and consolidated net income$210,467 $159,616 
_________________
(1) Other segment items include stock-based compensation, other research and development expenses, including the allocation of general corporate costs to research and development services and development cost reimbursements in connection with certain of our collaboration arrangements, and other income (expenses), net.
All of our long-lived assets are located in the U.S. See “Note 3. Revenues” for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.